Frequency of Autoantibodies on Non-Hodgkin Lymphoma

Abstract

(1) Background: Non-Hodgkin Lymphoma is a neoplasm that can significantly compromise the immune system, but timely assessment can change the patient outcome. In cancer, the activation of the immune system could lead to the secretion of autoantibodies. (2) Methods: A retrospective cohort study was performed from 2017 to 2019 in patients with Non-Hodgkin Lymphoma diagnosed with a biopsy. (3) Results: We included 39 patients who were newly diagnosed, untreated, and without any autoimmune disease previously reported. Thirty patients had the presence of autoantibodies (antiphospholipid antibodies, anti-cytoplasmic neutrophils antibodies, antinuclear antibodies), and nine were without autoantibodies. There were no statistical differences among groups regarding clinical, demographic, staging, and prognosis characteristics. Also, there were no differences in the outcomes of the patients after finishing chemotherapy and one year after initiating treatment. (4) Conclusions: Further investigations must be conducted regarding an extended panel of autoantibodies because the panel of autoantibodies in this study did not show a relationship between the presence and the clinical outcome of the patients.

Impact of Anti-nuclear Antibody Seropositivity on Clinicopathological Parameters, Treatment Response, and Survival in Lymphoma Patients

“…Charlotte Mörth et al found a significantly increased prevalence of ANA in females, which is already established for AD in general [5]. Regarding the association of ANA with the type of lymphoma, the AABC subtype of DLBCL has a higher tendency for AD and obviously for ANA too [14,10,3]. Contrary to this, we noticed ANA positivity in only 33% (03/10) of DLBCL-non-GCB and 36% (13/36) of overall DLBCL, respectively.…”

“…AD as a risk factor for the development of lymphoma is relatively better established; yet, the prevalence of AD diseases in patients with lymphoma and their impact on the outcome of this malignancy is relatively less explored [1,5,6]. Prevalence of AD in DLBCL patients has ranged from 17.3% to 22.5% as compared to the general population (03-13.8%) [5,6,8] [9][10][11]. Most of the earlier reports have some limitations like the random time of recruitment (before/after therapy), retrospective data, and variable definition of AD (based only on clinical features without biological markers) [1,5,9,11].…”

“…To overcome these limitations, we conducted a prospective study with two-point sampling and observed an ANA frequency of 27% in newly diagnosed lymphoma cases. Only a handful of data tried to explore the impact of AD or ANA positivity on lymphoma [5,[10][11][12][13]. Most clinical parameters in lymphoma patients didn't exhibit a significant association with ANA positivity; however, some demonstrated it as a marker of poor prognosis and relapse [11][12][13].…”

Antinuclear Antibodies Are Associated with an Increased Risk of Diffuse Large B-Cell Lymphoma

“…One hospital-based case-control study reported a higher prevalence of ANA as well as other autoimmune antibodies among lymphoma patients compared to healthy controls [29]. A retrospective cohort study found that 77% of non-Hodgkin lymphoma patients had autoantibodies at the time of diagnosis, with 44% of those testing positive for ANA [31]. Although we did not observe an increased risk of NHL overall with ANA in our study, we did observe a higher risk of NHL with the presence of at least one other autoimmune antibody.…”

Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective

“…B-cell non-Hodgkin lymphoma (NHL) collectively represents the most common type of hematologic malignancy [ 1 ]. While advances in chemotherapy, monoclonal antibodies, and stem cell transplantation have improved survival rates, many NHL patients remain resistant to therapy or experience relapse.…”